Form 8-K - Current report:
SEC Accession No. 0001193125-25-178022
Filing Date
2025-08-11
Accepted
2025-08-11 16:51:33
Documents
18
Period of Report
2025-08-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d56029d8k.htm   iXBRL 8-K 33497
2 EX-1.1 d56029dex11.htm EX-1.1 244053
3 EX-1.2 d56029dex12.htm EX-1.2 15628
4 EX-5.1 d56029dex51.htm EX-5.1 8181
8 GRAPHIC g56029g0811154707234.jpg GRAPHIC 4906
9 GRAPHIC g56029g0811154707520.jpg GRAPHIC 5737
10 GRAPHIC g56029g0811154707674.jpg GRAPHIC 2764
  Complete submission text file 0001193125-25-178022.txt   508273

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA smmt-20250811.xsd EX-101.SCH 2855
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE smmt-20250811_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE smmt-20250811_pre.xml EX-101.PRE 11264
20 EXTRACTED XBRL INSTANCE DOCUMENT d56029d8k_htm.xml XML 3644
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 251202714
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)